Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
40 hedge funds and large institutions have $14.2M invested in Aevi Genomic Medicine Inc in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 8 closing their positions.
9% less funds holding
Funds holding: 44 → 40 (-4)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
48% less capital invested
Capital invested by funds: $27.2M → $14.2M (-$13M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$318K |
| 2 |
BlackRock
New York
|
+$60K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$50.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.6K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$29.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.32M |
| 2 |
JP Morgan Chase
New York
|
-$203K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$63K |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$57.8K |
| 5 |
Renaissance Technologies
New York
|
-$43.8K |
GNMX Hedge Fund Activity: Q2 2018 in Review
40 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2018, worth a combined $14.2M — down 48% from $27.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GNMX and 4 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Wedbush Securities, opening a new position worth an estimated $318K. The largest seller was T. Rowe Price Associates, cutting an estimated $1.32M.
- 40 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2018, down from 44 in Q1 2018.
- Funds reported $14.2M of Aevi Genomic Medicine Inc stock for Q2 2018, down 48% quarter-over-quarter.
- 4 funds opened new Aevi Genomic Medicine Inc positions in Q2 2018 and 8 closed out, a net change of -4 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q2 2018 was Wedbush Securities, an estimated $318K added.
- The largest Aevi Genomic Medicine Inc seller in Q2 2018 was T. Rowe Price Associates, an estimated $1.32M sold.
Based on aggregated 13F filings for Q2 2018.